Industry Research Reports
Home > Reports > Medical Devices & Consumables > KRAS Inhibitor - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
KRAS Inhibitor - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
Industry: Medical Devices & Consumables
Published Date: 2025-03-10
Pages: 94 Pages
Report ld: 4617358
Request Sample
Customized Report
- Description
- Table of Contents
- Table of Figures
- Related Reports
PDF Download
- Description
- Table of Contents
- Table of Figures
- Related Reports
- PDF Download
KRAS Inhibitor Market Size(US$)
CAGR 2025-2031
8.3%
Market Size,2031
USD 232
Million
Market Snapshot
Market Size in 2025 (Value)
US$ 144 million
Market Forecast in 2031(Value)
US$ 232 million
CAGR
8.3%
Years Considered
2020-2031
Base Year
2025
Forecast Period
2025-2031
Source: Secondary research, interviews with experts, and QYResearch analysis
The global market for KRAS Inhibitor was estimated to be worth US$ 134 million in 2024 and is forecast to a readjusted size of US$ 232 million by 2031 with a CAGR of 8.3% during the forecast period 2025-2031.
KRAS inhibitors are a class of targeted cancer therapies designed to block the activity of the KRAS protein, a common driver of cancer, particularly in pancreatic, colorectal, and lung cancers. KRAS mutations are notoriously difficult to target because the protein has a smooth surface with few pockets for drug binding. However, recent advances have led to the development of specific inhibitors, such as sotorasib and adagrasib, which target the G12C mutation in KRAS, a mutation present in a subset of cancers. These inhibitors work by irreversibly binding to the mutant KRAS protein, preventing it from signaling the uncontrolled cell growth that leads to cancer. While these drugs have shown promise, they are not universally effective, and resistance often develops, leading to ongoing research to improve their efficacy and expand their use to other KRAS mutations.
North American market for KRAS Inhibitor was valued at $ million in 2024 and will reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for KRAS Inhibitor was valued at $ million in 2024 and will reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for KRAS Inhibitor was valued at $ million in 2024 and will reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The global key companies of KRAS Inhibitor include Amgen, Boehringer Ingelheim, BridgeBio Pharma, Erasca, Innovent Biologics, Incyte, Mirati Therapeutics, Novartis, Jemincare, Cardiff Oncology, etc. In 2024, the global five largest players hold a share approximately % in terms of revenue.
This report aims to provide a comprehensive presentation of the global market for KRAS Inhibitor, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of KRAS Inhibitor by region & country, by Type, and by Application.
The KRAS Inhibitor market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding KRAS Inhibitor.
MARKET SEGMENTATION
By Company
- Amgen
- Boehringer Ingelheim
- BridgeBio Pharma
- Erasca
- Innovent Biologics
- Incyte
- Mirati Therapeutics
- Novartis
- Jemincare
- Cardiff Oncology
Consumption by Region
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia-Pacific
- Europe
- Germany
- France
- U.K.
- Italy
- Netherlands
- Nordic Countries
- Rest of Europe
- Latin America
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA
Segment by Type
- Lung Cancer
- Pancreatic Cancer
- Colorectal Cancer
- Others
Segment by Application
- Clinic Laboratories
- Cancer Diagnostic Centres
- Hospitals
- Others
CHAPTER OUTLINE
Chapter 1: Introduces the report scope of the report, global total market size (value, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of KRAS Inhibitor manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of KRAS Inhibitor in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of KRAS Inhibitor in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
QYRESEARCH'S STRENGTHS
Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Compound Chocolate value chain, addressing:
Market entry risks/opportunities by region
We identify regional market threats and growth prospects to guide your overseas layout.
Product mix optimization based on local practices
We adjust product portfolios in line with local consumption habits.
Competitor tactics in fragmented vs. consolidated markets
We unpack rivals’ operation strategies for scattered and highly concentrated industries.
Full Research Coverage
We cover competition landscape, full supply chain and quantified market size data, and deliver tailor-made customized surveys to meet your unique business demands.
19 Years Industry Expertise
We own self-owned massive exclusive databases, backed by 19 years of global market research experience across thousands of sectors.
24/7 Fast Report Delivery
Our team operates 24 hours a day, 365 days a year, enabling ultra-fast report turnaround to respond to your research needs efficiently.
Localized Strategic Analysis
We integrate regional risk assessment, localized product optimization and competitor analysis to deliver actionable market strategies.
Market entry risks/opportunities by region
All data is cross-verified from multiple industry sources to deliver thorough, precise analysis that supports reliable corporate strategic decisions.
Market entry risks/opportunities by region
We provide responsive, dedicated after-sales support to resolve all follow-up inquiries about reports, data and industry interpretation.
TABLE OF CONTENTS
1 Market Overview
1.1 KRAS Inhibitor Product Introduction
1.2 Global KRAS Inhibitor Market Size Forecast
1.2.1 Global KRAS Inhibitor Sales Value (2020-2031)
1.2.2 Global KRAS Inhibitor Sales Volume (2020-2031)
1.2.3 Global KRAS Inhibitor Sales Price (2020-2031)
1.3 KRAS Inhibitor Market Trends & Drivers
1.3.1 KRAS Inhibitor Industry Trends
1.3.2 KRAS Inhibitor Market Drivers & Opportunity
1.3.3 KRAS Inhibitor Market Challenges
1.3.4 KRAS Inhibitor Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global KRAS Inhibitor Players Revenue Ranking (2024)
2.2 Global KRAS Inhibitor Revenue by Company (2020-2025)
2.3 Global KRAS Inhibitor Players Sales Volume Ranking (2024)
2.4 Global KRAS Inhibitor Sales Volume by Company Players (2020-2025)
2.5 Global KRAS Inhibitor Average Price by Company (2020-2025)
2.6 Key Manufacturers KRAS Inhibitor Manufacturing Base and Headquarters
2.7 Key Manufacturers KRAS Inhibitor Product Offered
2.8 Key Manufacturers Time to Begin Mass Production of KRAS Inhibitor
2.9 KRAS Inhibitor Market Competitive Analysis
2.9.1 KRAS Inhibitor Market Concentration Rate (2020-2025)
2.9.2 Global 5 and 10 Largest Manufacturers by KRAS Inhibitor Revenue in 2024
2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in KRAS Inhibitor as of 2024)
2.10 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Lung Cancer
3.1.2 Pancreatic Cancer
3.1.3 Colorectal Cancer
3.1.4 Others
3.2 Global KRAS Inhibitor Sales Value by Type
3.2.1 Global KRAS Inhibitor Sales Value by Type (2020 VS 2024 VS 2031)
3.2.2 Global KRAS Inhibitor Sales Value, by Type (2020-2031)
3.2.3 Global KRAS Inhibitor Sales Value, by Type (%) (2020-2031)
3.3 Global KRAS Inhibitor Sales Volume by Type
3.3.1 Global KRAS Inhibitor Sales Volume by Type (2020 VS 2024 VS 2031)
3.3.2 Global KRAS Inhibitor Sales Volume, by Type (2020-2031)
3.3.3 Global KRAS Inhibitor Sales Volume, by Type (%) (2020-2031)
3.4 Global KRAS Inhibitor Average Price by Type (2020-2031)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Clinic Laboratories
4.1.2 Cancer Diagnostic Centres
4.1.3 Hospitals
4.1.4 Others
4.2 Global KRAS Inhibitor Sales Value by Application
4.2.1 Global KRAS Inhibitor Sales Value by Application (2020 VS 2024 VS 2031)
4.2.2 Global KRAS Inhibitor Sales Value, by Application (2020-2031)
4.2.3 Global KRAS Inhibitor Sales Value, by Application (%) (2020-2031)
4.3 Global KRAS Inhibitor Sales Volume by Application
4.3.1 Global KRAS Inhibitor Sales Volume by Application (2020 VS 2024 VS 2031)
4.3.2 Global KRAS Inhibitor Sales Volume, by Application (2020-2031)
4.3.3 Global KRAS Inhibitor Sales Volume, by Application (%) (2020-2031)
4.4 Global KRAS Inhibitor Average Price by Application (2020-2031)
5 Segmentation by Region
5.1 Global KRAS Inhibitor Sales Value by Region
5.1.1 Global KRAS Inhibitor Sales Value by Region: 2020 VS 2024 VS 2031
5.1.2 Global KRAS Inhibitor Sales Value by Region (2020-2025)
5.1.3 Global KRAS Inhibitor Sales Value by Region (2026-2031)
5.1.4 Global KRAS Inhibitor Sales Value by Region (%), (2020-2031)
5.2 Global KRAS Inhibitor Sales Volume by Region
5.2.1 Global KRAS Inhibitor Sales Volume by Region: 2020 VS 2024 VS 2031
5.2.2 Global KRAS Inhibitor Sales Volume by Region (2020-2025)
5.2.3 Global KRAS Inhibitor Sales Volume by Region (2026-2031)
5.2.4 Global KRAS Inhibitor Sales Volume by Region (%), (2020-2031)
5.3 Global KRAS Inhibitor Average Price by Region (2020-2031)
5.4 North America
5.4.1 North America KRAS Inhibitor Sales Value, 2020-2031
5.4.2 North America KRAS Inhibitor Sales Value by Country (%), 2024 VS 2031
5.5 Europe
5.5.1 Europe KRAS Inhibitor Sales Value, 2020-2031
5.5.2 Europe KRAS Inhibitor Sales Value by Country (%), 2024 VS 2031
5.6 Asia Pacific
5.6.1 Asia Pacific KRAS Inhibitor Sales Value, 2020-2031
5.6.2 Asia Pacific KRAS Inhibitor Sales Value by Region (%), 2024 VS 2031
5.7 South America
5.7.1 South America KRAS Inhibitor Sales Value, 2020-2031
5.7.2 South America KRAS Inhibitor Sales Value by Country (%), 2024 VS 2031
5.8 Middle East & Africa
5.8.1 Middle East & Africa KRAS Inhibitor Sales Value, 2020-2031
5.8.2 Middle East & Africa KRAS Inhibitor Sales Value by Country (%), 2024 VS 2031
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions KRAS Inhibitor Sales Value Growth Trends, 2020 VS 2024 VS 2031
6.2 Key Countries/Regions KRAS Inhibitor Sales Value and Sales Volume
6.2.1 Key Countries/Regions KRAS Inhibitor Sales Value, 2020-2031
6.2.2 Key Countries/Regions KRAS Inhibitor Sales Volume, 2020-2031
6.3 United States
6.3.1 United States KRAS Inhibitor Sales Value, 2020-2031
6.3.2 United States KRAS Inhibitor Sales Value by Type (%), 2024 VS 2031
6.3.3 United States KRAS Inhibitor Sales Value by Application, 2024 VS 2031
6.4 Europe
6.4.1 Europe KRAS Inhibitor Sales Value, 2020-2031
6.4.2 Europe KRAS Inhibitor Sales Value by Type (%), 2024 VS 2031
6.4.3 Europe KRAS Inhibitor Sales Value by Application, 2024 VS 2031
6.5 China
6.5.1 China KRAS Inhibitor Sales Value, 2020-2031
6.5.2 China KRAS Inhibitor Sales Value by Type (%), 2024 VS 2031
6.5.3 China KRAS Inhibitor Sales Value by Application, 2024 VS 2031
6.6 Japan
6.6.1 Japan KRAS Inhibitor Sales Value, 2020-2031
6.6.2 Japan KRAS Inhibitor Sales Value by Type (%), 2024 VS 2031
6.6.3 Japan KRAS Inhibitor Sales Value by Application, 2024 VS 2031
6.7 South Korea
6.7.1 South Korea KRAS Inhibitor Sales Value, 2020-2031
6.7.2 South Korea KRAS Inhibitor Sales Value by Type (%), 2024 VS 2031
6.7.3 South Korea KRAS Inhibitor Sales Value by Application, 2024 VS 2031
6.8 Southeast Asia
6.8.1 Southeast Asia KRAS Inhibitor Sales Value, 2020-2031
6.8.2 Southeast Asia KRAS Inhibitor Sales Value by Type (%), 2024 VS 2031
6.8.3 Southeast Asia KRAS Inhibitor Sales Value by Application, 2024 VS 2031
6.9 India
6.9.1 India KRAS Inhibitor Sales Value, 2020-2031
6.9.2 India KRAS Inhibitor Sales Value by Type (%), 2024 VS 2031
6.9.3 India KRAS Inhibitor Sales Value by Application, 2024 VS 2031
7 Company Profiles
7.1 Amgen
7.1.1 Amgen Company Information
7.1.2 Amgen Introduction and Business Overview
7.1.3 Amgen KRAS Inhibitor Sales, Revenue, Price and Gross Margin (2020-2025)
7.1.4 Amgen KRAS Inhibitor Product Offerings
7.1.5 Amgen Recent Development
7.2 Boehringer Ingelheim
7.2.1 Boehringer Ingelheim Company Information
7.2.2 Boehringer Ingelheim Introduction and Business Overview
7.2.3 Boehringer Ingelheim KRAS Inhibitor Sales, Revenue, Price and Gross Margin (2020-2025)
7.2.4 Boehringer Ingelheim KRAS Inhibitor Product Offerings
7.2.5 Boehringer Ingelheim Recent Development
7.3 BridgeBio Pharma
7.3.1 BridgeBio Pharma Company Information
7.3.2 BridgeBio Pharma Introduction and Business Overview
7.3.3 BridgeBio Pharma KRAS Inhibitor Sales, Revenue, Price and Gross Margin (2020-2025)
7.3.4 BridgeBio Pharma KRAS Inhibitor Product Offerings
7.3.5 BridgeBio Pharma Recent Development
7.4 Erasca
7.4.1 Erasca Company Information
7.4.2 Erasca Introduction and Business Overview
7.4.3 Erasca KRAS Inhibitor Sales, Revenue, Price and Gross Margin (2020-2025)
7.4.4 Erasca KRAS Inhibitor Product Offerings
7.4.5 Erasca Recent Development
7.5 Innovent Biologics
7.5.1 Innovent Biologics Company Information
7.5.2 Innovent Biologics Introduction and Business Overview
7.5.3 Innovent Biologics KRAS Inhibitor Sales, Revenue, Price and Gross Margin (2020-2025)
7.5.4 Innovent Biologics KRAS Inhibitor Product Offerings
7.5.5 Innovent Biologics Recent Development
7.6 Incyte
7.6.1 Incyte Company Information
7.6.2 Incyte Introduction and Business Overview
7.6.3 Incyte KRAS Inhibitor Sales, Revenue, Price and Gross Margin (2020-2025)
7.6.4 Incyte KRAS Inhibitor Product Offerings
7.6.5 Incyte Recent Development
7.7 Mirati Therapeutics
7.7.1 Mirati Therapeutics Company Information
7.7.2 Mirati Therapeutics Introduction and Business Overview
7.7.3 Mirati Therapeutics KRAS Inhibitor Sales, Revenue, Price and Gross Margin (2020-2025)
7.7.4 Mirati Therapeutics KRAS Inhibitor Product Offerings
7.7.5 Mirati Therapeutics Recent Development
7.8 Novartis
7.8.1 Novartis Company Information
7.8.2 Novartis Introduction and Business Overview
7.8.3 Novartis KRAS Inhibitor Sales, Revenue, Price and Gross Margin (2020-2025)
7.8.4 Novartis KRAS Inhibitor Product Offerings
7.8.5 Novartis Recent Development
7.9 Jemincare
7.9.1 Jemincare Company Information
7.9.2 Jemincare Introduction and Business Overview
7.9.3 Jemincare KRAS Inhibitor Sales, Revenue, Price and Gross Margin (2020-2025)
7.9.4 Jemincare KRAS Inhibitor Product Offerings
7.9.5 Jemincare Recent Development
7.10 Cardiff Oncology
7.10.1 Cardiff Oncology Company Information
7.10.2 Cardiff Oncology Introduction and Business Overview
7.10.3 Cardiff Oncology KRAS Inhibitor Sales, Revenue, Price and Gross Margin (2020-2025)
7.10.4 Cardiff Oncology KRAS Inhibitor Product Offerings
7.10.5 Cardiff Oncology Recent Development
8 Industry Chain Analysis
8.1 KRAS Inhibitor Industrial Chain
8.2 KRAS Inhibitor Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 KRAS Inhibitor Sales Model
8.5.2 Sales Channel
8.5.3 KRAS Inhibitor Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.1.1 Research Programs/Design
10.1.1.2 Market Size Estimation
10.1.1.3 Market Breakdown and Data Triangulation
10.1.2 Data Source
10.1.2.1 Secondary Sources
10.1.2.2 Primary Sources
10.2 Author Details
10.3 Disclaimer
TABLE OF FIGURES
List of Tables
Table 1. KRAS Inhibitor Market Trends
Table 2. KRAS Inhibitor Market Drivers & Opportunity
Table 3. KRAS Inhibitor Market Challenges
Table 4. KRAS Inhibitor Market Restraints
Table 5. Global KRAS Inhibitor Revenue by Company (2020-2025) & (US$ Million)
Table 6. Global KRAS Inhibitor Revenue Market Share by Company (2020-2025)
Table 7. Global KRAS Inhibitor Sales Volume by Company (2020-2025) & (K Units)
Table 8. Global KRAS Inhibitor Sales Volume Market Share by Company (2020-2025)
Table 9. Global Market KRAS Inhibitor Price by Company (2020-2025) & (US$/Unit)
Table 10. Key Manufacturers KRAS Inhibitor Manufacturing Base and Headquarters
Table 11. Key Manufacturers KRAS Inhibitor Product Type
Table 12. Key Manufacturers Time to Begin Mass Production of KRAS Inhibitor
Table 13. Global KRAS Inhibitor Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in KRAS Inhibitor as of 2024)
Table 15. Mergers & Acquisitions, Expansion Plans
Table 16. Global KRAS Inhibitor Sales Value by Type: 2020 VS 2024 VS 2031 (US$ Million)
Table 17. Global KRAS Inhibitor Sales Value by Type (2020-2025) & (US$ Million)
Table 18. Global KRAS Inhibitor Sales Value by Type (2026-2031) & (US$ Million)
Table 19. Global KRAS Inhibitor Sales Market Share in Value by Type (2020-2025)
Table 20. Global KRAS Inhibitor Sales Market Share in Value by Type (2026-2031)
Table 21. Global KRAS Inhibitor Sales Volume by Type: 2020 VS 2024 VS 2031 (K Units)
Table 22. Global KRAS Inhibitor Sales Volume by Type (2020-2025) & (K Units)
Table 23. Global KRAS Inhibitor Sales Volume by Type (2026-2031) & (K Units)
Table 24. Global KRAS Inhibitor Sales Market Share in Volume by Type (2020-2025)
Table 25. Global KRAS Inhibitor Sales Market Share in Volume by Type (2026-2031)
Table 26. Global KRAS Inhibitor Price by Type (2020-2025) & (US$/Unit)
Table 27. Global KRAS Inhibitor Price by Type (2026-2031) & (US$/Unit)
Table 28. Global KRAS Inhibitor Sales Value by Application: 2020 VS 2024 VS 2031 (US$ Million)
Table 29. Global KRAS Inhibitor Sales Value by Application (2020-2025) & (US$ Million)
Table 30. Global KRAS Inhibitor Sales Value by Application (2026-2031) & (US$ Million)
Table 31. Global KRAS Inhibitor Sales Market Share in Value by Application (2020-2025)
Table 32. Global KRAS Inhibitor Sales Market Share in Value by Application (2026-2031)
Table 33. Global KRAS Inhibitor Sales Volume by Application: 2020 VS 2024 VS 2031 (K Units)
Table 34. Global KRAS Inhibitor Sales Volume by Application (2020-2025) & (K Units)
Table 35. Global KRAS Inhibitor Sales Volume by Application (2026-2031) & (K Units)
Table 36. Global KRAS Inhibitor Sales Market Share in Volume by Application (2020-2025)
Table 37. Global KRAS Inhibitor Sales Market Share in Volume by Application (2026-2031)
Table 38. Global KRAS Inhibitor Price by Application (2020-2025) & (US$/Unit)
Table 39. Global KRAS Inhibitor Price by Application (2026-2031) & (US$/Unit)
Table 40. Global KRAS Inhibitor Sales Value by Region, (2020 VS 2024 VS 2031) & (US$ Million)
Table 41. Global KRAS Inhibitor Sales Value by Region (2020-2025) & (US$ Million)
Table 42. Global KRAS Inhibitor Sales Value by Region (2026-2031) & (US$ Million)
Table 43. Global KRAS Inhibitor Sales Value by Region (2020-2025) & (%)
Table 44. Global KRAS Inhibitor Sales Value by Region (2026-2031) & (%)
Table 45. Global KRAS Inhibitor Sales Volume by Region (K Units): 2020 VS 2024 VS 2031
Table 46. Global KRAS Inhibitor Sales Volume by Region (2020-2025) & (K Units)
Table 47. Global KRAS Inhibitor Sales Volume by Region (2026-2031) & (K Units)
Table 48. Global KRAS Inhibitor Sales Volume by Region (2020-2025) & (%)
Table 49. Global KRAS Inhibitor Sales Volume by Region (2026-2031) & (%)
Table 50. Global KRAS Inhibitor Average Price by Region (2020-2025) & (US$/Unit)
Table 51. Global KRAS Inhibitor Average Price by Region (2026-2031) & (US$/Unit)
Table 52. Key Countries/Regions KRAS Inhibitor Sales Value Growth Trends, (US$ Million): 2020 VS 2024 VS 2031
Table 53. Key Countries/Regions KRAS Inhibitor Sales Value, (2020-2025) & (US$ Million)
Table 54. Key Countries/Regions KRAS Inhibitor Sales Value, (2026-2031) & (US$ Million)
Table 55. Key Countries/Regions KRAS Inhibitor Sales Volume, (2020-2025) & (K Units)
Table 56. Key Countries/Regions KRAS Inhibitor Sales Volume, (2026-2031) & (K Units)
Table 57. Amgen Company Information
Table 58. Amgen Introduction and Business Overview
Table 59. Amgen KRAS Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 60. Amgen KRAS Inhibitor Product Offerings
Table 61. Amgen Recent Development
Table 62. Boehringer Ingelheim Company Information
Table 63. Boehringer Ingelheim Introduction and Business Overview
Table 64. Boehringer Ingelheim KRAS Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 65. Boehringer Ingelheim KRAS Inhibitor Product Offerings
Table 66. Boehringer Ingelheim Recent Development
Table 67. BridgeBio Pharma Company Information
Table 68. BridgeBio Pharma Introduction and Business Overview
Table 69. BridgeBio Pharma KRAS Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 70. BridgeBio Pharma KRAS Inhibitor Product Offerings
Table 71. BridgeBio Pharma Recent Development
Table 72. Erasca Company Information
Table 73. Erasca Introduction and Business Overview
Table 74. Erasca KRAS Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 75. Erasca KRAS Inhibitor Product Offerings
Table 76. Erasca Recent Development
Table 77. Innovent Biologics Company Information
Table 78. Innovent Biologics Introduction and Business Overview
Table 79. Innovent Biologics KRAS Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 80. Innovent Biologics KRAS Inhibitor Product Offerings
Table 81. Innovent Biologics Recent Development
Table 82. Incyte Company Information
Table 83. Incyte Introduction and Business Overview
Table 84. Incyte KRAS Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 85. Incyte KRAS Inhibitor Product Offerings
Table 86. Incyte Recent Development
Table 87. Mirati Therapeutics Company Information
Table 88. Mirati Therapeutics Introduction and Business Overview
Table 89. Mirati Therapeutics KRAS Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 90. Mirati Therapeutics KRAS Inhibitor Product Offerings
Table 91. Mirati Therapeutics Recent Development
Table 92. Novartis Company Information
Table 93. Novartis Introduction and Business Overview
Table 94. Novartis KRAS Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 95. Novartis KRAS Inhibitor Product Offerings
Table 96. Novartis Recent Development
Table 97. Jemincare Company Information
Table 98. Jemincare Introduction and Business Overview
Table 99. Jemincare KRAS Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 100. Jemincare KRAS Inhibitor Product Offerings
Table 101. Jemincare Recent Development
Table 102. Cardiff Oncology Company Information
Table 103. Cardiff Oncology Introduction and Business Overview
Table 104. Cardiff Oncology KRAS Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 105. Cardiff Oncology KRAS Inhibitor Product Offerings
Table 106. Cardiff Oncology Recent Development
Table 107. Key Raw Materials Lists
Table 108. Raw Materials Key Suppliers Lists
Table 109. KRAS Inhibitor Downstream Customers
Table 110. KRAS Inhibitor Distributors List
Table 111. Research Programs/Design for This Report
Table 112. Key Data Information from Secondary Sources
Table 113. Key Data Information from Primary Sources
List of Figures
Figure 1. KRAS Inhibitor Product Picture
Figure 2. Global KRAS Inhibitor Sales Value, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Global KRAS Inhibitor Sales Value (2020-2031) & (US$ Million)
Figure 4. Global KRAS Inhibitor Sales Volume (2020-2031) & (K Units)
Figure 5. Global KRAS Inhibitor Sales Price (2020-2031) & (US$/Unit)
Figure 6. KRAS Inhibitor Report Years Considered
Figure 7. Global KRAS Inhibitor Players Revenue Ranking (2024) & (US$ Million)
Figure 8. Global KRAS Inhibitor Players Sales Volume Ranking (2024) & (K Units)
Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by KRAS Inhibitor Revenue in 2024
Figure 10. KRAS Inhibitor Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 11. Lung Cancer Picture
Figure 12. Pancreatic Cancer Picture
Figure 13. Colorectal Cancer Picture
Figure 14. Others Picture
Figure 15. Global KRAS Inhibitor Sales Value by Type (2020 VS 2024 VS 2031) & (US$ Million)
Figure 16. Global KRAS Inhibitor Sales Value Market Share by Type, 2024 & 2031
Figure 17. Global KRAS Inhibitor Sales Volume by Type (2020 VS 2024 VS 2031) & (K Units)
Figure 18. Global KRAS Inhibitor Sales Volume Market Share by Type, 2024 & 2031
Figure 19. Global KRAS Inhibitor Price by Type (2020-2031) & (US$/Unit)
Figure 20. Product Picture of Clinic Laboratories
Figure 21. Product Picture of Cancer Diagnostic Centres
Figure 22. Product Picture of Hospitals
Figure 23. Product Picture of Others
Figure 24. Global KRAS Inhibitor Sales Value by Application (2020 VS 2024 VS 2031) & (US$ Million)
Figure 25. Global KRAS Inhibitor Sales Value Market Share by Application, 2024 & 2031
Figure 26. Global KRAS Inhibitor Sales Volume by Application (2020 VS 2024 VS 2031) & (K Units)
Figure 27. Global KRAS Inhibitor Sales Volume Market Share by Application, 2024 & 2031
Figure 28. Global KRAS Inhibitor Price by Application (2020-2031) & (US$/Unit)
Figure 29. North America KRAS Inhibitor Sales Value (2020-2031) & (US$ Million)
Figure 30. North America KRAS Inhibitor Sales Value by Country (%), 2024 VS 2031
Figure 31. Europe KRAS Inhibitor Sales Value, (2020-2031) & (US$ Million)
Figure 32. Europe KRAS Inhibitor Sales Value by Country (%), 2024 VS 2031
Figure 33. Asia Pacific KRAS Inhibitor Sales Value, (2020-2031) & (US$ Million)
Figure 34. Asia Pacific KRAS Inhibitor Sales Value by Region (%), 2024 VS 2031
Figure 35. South America KRAS Inhibitor Sales Value, (2020-2031) & (US$ Million)
Figure 36. South America KRAS Inhibitor Sales Value by Country (%), 2024 VS 2031
Figure 37. Middle East & Africa KRAS Inhibitor Sales Value, (2020-2031) & (US$ Million)
Figure 38. Middle East & Africa KRAS Inhibitor Sales Value by Country (%), 2024 VS 2031
Figure 39. Key Countries/Regions KRAS Inhibitor Sales Value (%), (2020-2031)
Figure 40. Key Countries/Regions KRAS Inhibitor Sales Volume (%), (2020-2031)
Figure 41. United States KRAS Inhibitor Sales Value, (2020-2031) & (US$ Million)
Figure 42. United States KRAS Inhibitor Sales Value by Type (%), 2024 VS 2031
Figure 43. United States KRAS Inhibitor Sales Value by Application (%), 2024 VS 2031
Figure 44. Europe KRAS Inhibitor Sales Value, (2020-2031) & (US$ Million)
Figure 45. Europe KRAS Inhibitor Sales Value by Type (%), 2024 VS 2031
Figure 46. Europe KRAS Inhibitor Sales Value by Application (%), 2024 VS 2031
Figure 47. China KRAS Inhibitor Sales Value, (2020-2031) & (US$ Million)
Figure 48. China KRAS Inhibitor Sales Value by Type (%), 2024 VS 2031
Figure 49. China KRAS Inhibitor Sales Value by Application (%), 2024 VS 2031
Figure 50. Japan KRAS Inhibitor Sales Value, (2020-2031) & (US$ Million)
Figure 51. Japan KRAS Inhibitor Sales Value by Type (%), 2024 VS 2031
Figure 52. Japan KRAS Inhibitor Sales Value by Application (%), 2024 VS 2031
Figure 53. South Korea KRAS Inhibitor Sales Value, (2020-2031) & (US$ Million)
Figure 54. South Korea KRAS Inhibitor Sales Value by Type (%), 2024 VS 2031
Figure 55. South Korea KRAS Inhibitor Sales Value by Application (%), 2024 VS 2031
Figure 56. Southeast Asia KRAS Inhibitor Sales Value, (2020-2031) & (US$ Million)
Figure 57. Southeast Asia KRAS Inhibitor Sales Value by Type (%), 2024 VS 2031
Figure 58. Southeast Asia KRAS Inhibitor Sales Value by Application (%), 2024 VS 2031
Figure 59. India KRAS Inhibitor Sales Value, (2020-2031) & (US$ Million)
Figure 60. India KRAS Inhibitor Sales Value by Type (%), 2024 VS 2031
Figure 61. India KRAS Inhibitor Sales Value by Application (%), 2024 VS 2031
Figure 62. KRAS Inhibitor Industrial Chain
Figure 63. KRAS Inhibitor Manufacturing Cost Structure
Figure 64. Channels of Distribution (Direct Sales, and Distribution)
Figure 65. Bottom-up and Top-down Approaches for This Report
Figure 66. Data Triangulation
Figure 67. Key Executives Interviewed
KEY QUESTIONS ADDRESSED BY THE REPORT
Which region is expected to have the highest market share?
For each regional market, the report conducted in-depth comparative analysis from multiple dimensions such as market size, 8.3% compound annual growth rate, market demand, industrial structure, policy environment, and the layout of major enterprises. It systematically summarized the market characteristics and competitive environment of different regions. At the same time, it also focused on analyzing the demand structure, market growth drivers, and investment environment of each region, providing valuable references for enterprises to identify key regional markets, formulate global market layouts and sales strategies.
Which companies rank high in the global KRAS Inhibitor market?
What was the global market size of KRAS Inhibitor in 2025?
What is the annual compound growth rate of the global KRAS Inhibitor market size from 2025 to 2031?
What was the global market size of KRAS Inhibitor in 2031?
Related Reports
Global KRAS Inhibitor Market Outlook, In‑Depth Analysis & Forecast to 2032
The global KRAS Inhibitor market is projected to grow from US$ 144 million in 2025 to US$ 250 million by 2032, at a CAGR of 8.3% (2026-2032), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.
Published Date: 2026-03-26
Pages: 133
USD 4900.00
(Single User License)
Global KRAS Inhibitor Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
The global KRAS Inhibitor market size was US$ 144 million in 2025 and is forecast to reach a readjusted size of US$ 250 million by 2032 with a CAGR of 8.3% during the forecast period 2026-2032.
Published Date: 2026-03-26
Pages: 78
USD 4250.00
(Single User License)
KRAS Inhibitor- Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for KRAS Inhibitor was estimated to be worth US$ 144 million in 2025 and is projected to reach US$ 250 million, growing at a CAGR of 8.3% from 2026 to 2032.
Published Date: 2026-01-09
Pages: 100
USD 3950.00
(Single User License)
Global KRAS Inhibitor Market Research Report 2026
The global KRAS Inhibitor market was valued at US$ 144 million in 2025 and is anticipated to reach US$ 250 million by 2032, at a CAGR of 8.3% from 2026 to 2032.
Published Date: 2026-01-09
Pages: 109
USD 2900.00
(Single User License)
Global KRAS Inhibitor Market Outlook, In‑Depth Analysis & Forecast to 2031
The global KRAS Inhibitor market is projected to grow from US$ 134 million in 2024 to US$ 232 million by 2031, at a CAGR of 8.3% (2025-2031), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.
Published Date: 2025-08-05
Pages: 131
USD 4900.00
(Single User License)
Global KRAS Inhibitor Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global KRAS Inhibitor market size was US$ 134 million in 2024 and is forecast to a readjusted size of US$ 232 million by 2031 with a CAGR of 8.3% during the forecast period 2025-2031.
Published Date: 2025-08-01
Pages: 78
USD 4250.00
(Single User License)
Global KRAS Inhibitor Market Research Report 2025
The global market for KRAS Inhibitor was valued at US$ 134 million in the year 2024 and is projected to reach a revised size of US$ 232 million by 2031, growing at a CAGR of 8.3% during the forecast period.
Published Date: 2025-03-10
Pages: 82
USD 2900.00
(Single User License)
Global and United States KRAS Inhibitor Market Report & Forecast 2024-2030
KRAS inhibitors are a class of targeted cancer therapies designed to block the activity of the KRAS protein, a common driver of cancer, particularly in pancreatic, colorectal, and lung cancers. KRAS mutations are notoriously difficult to target because the protein has a smooth surface with few pockets for drug binding. However, recent advances have led to the development of specific inhibitors, such as sotorasib and adagrasib, which target the G12C mutation in KRAS, a mutation present in a subset of cancers. These inhibitors work by irreversibly binding to the mutant KRAS protein, preventing it from signaling the uncontrolled cell growth that leads to cancer. While these drugs have shown promise, they are not universally effective, and resistance often develops, leading to ongoing research to improve their efficacy and expand their use to other KRAS mutations.
Published Date: 2024-09-11
Pages: 120
USD 4350.00
(Single User License)
Global KRAS Inhibitor Market Research Report 2024
KRAS inhibitors are a class of targeted cancer therapies designed to block the activity of the KRAS protein, a common driver of cancer, particularly in pancreatic, colorectal, and lung cancers. KRAS mutations are notoriously difficult to target because the protein has a smooth surface with few pockets for drug binding. However, recent advances have led to the development of specific inhibitors, such as sotorasib and adagrasib, which target the G12C mutation in KRAS, a mutation present in a subset of cancers. These inhibitors work by irreversibly binding to the mutant KRAS protein, preventing it from signaling the uncontrolled cell growth that leads to cancer. While these drugs have shown promise, they are not universally effective, and resistance often develops, leading to ongoing research to improve their efficacy and expand their use to other KRAS mutations.
Published Date: 2024-09-11
Pages: 78
USD 2900.00
(Single User License)
Global KRAS Inhibitor Market Insights, Forecast to 2030
KRAS inhibitors are a class of targeted cancer therapies designed to block the activity of the KRAS protein, a common driver of cancer, particularly in pancreatic, colorectal, and lung cancers. KRAS mutations are notoriously difficult to target because the protein has a smooth surface with few pockets for drug binding. However, recent advances have led to the development of specific inhibitors, such as sotorasib and adagrasib, which target the G12C mutation in KRAS, a mutation present in a subset of cancers. These inhibitors work by irreversibly binding to the mutant KRAS protein, preventing it from signaling the uncontrolled cell growth that leads to cancer. While these drugs have shown promise, they are not universally effective, and resistance often develops, leading to ongoing research to improve their efficacy and expand their use to other KRAS mutations.
Published Date: 2024-09-11
Pages: 139
USD 4900.00
(Single User License)
Global KRAS Inhibitor Market Outlook, In‑Depth Analysis & Forecast to 2032
The global KRAS Inhibitor market is projected to grow from US$ 144 million in 2025 to US$ 250 million by 2032, at a CAGR of 8.3% (2026-2032), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.
Published: 2026-03-26
Pages: 133
USD 4900.00 (Single User License)Global KRAS Inhibitor Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
The global KRAS Inhibitor market size was US$ 144 million in 2025 and is forecast to reach a readjusted size of US$ 250 million by 2032 with a CAGR of 8.3% during the forecast period 2026-2032.
Published: 2026-03-26
Pages: 78
USD 4250.00 (Single User License)KRAS Inhibitor- Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for KRAS Inhibitor was estimated to be worth US$ 144 million in 2025 and is projected to reach US$ 250 million, growing at a CAGR of 8.3% from 2026 to 2032.
Published: 2026-01-09
Pages: 100
USD 3950.00 (Single User License)Global KRAS Inhibitor Market Research Report 2026
The global KRAS Inhibitor market was valued at US$ 144 million in 2025 and is anticipated to reach US$ 250 million by 2032, at a CAGR of 8.3% from 2026 to 2032.
Published: 2026-01-09
Pages: 109
USD 2900.00 (Single User License)Global KRAS Inhibitor Market Outlook, In‑Depth Analysis & Forecast to 2031
The global KRAS Inhibitor market is projected to grow from US$ 134 million in 2024 to US$ 232 million by 2031, at a CAGR of 8.3% (2025-2031), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.
Published: 2025-08-05
Pages: 131
USD 4900.00 (Single User License)Global KRAS Inhibitor Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global KRAS Inhibitor market size was US$ 134 million in 2024 and is forecast to a readjusted size of US$ 232 million by 2031 with a CAGR of 8.3% during the forecast period 2025-2031.
Published: 2025-08-01
Pages: 78
USD 4250.00 (Single User License)Global KRAS Inhibitor Market Research Report 2025
The global market for KRAS Inhibitor was valued at US$ 134 million in the year 2024 and is projected to reach a revised size of US$ 232 million by 2031, growing at a CAGR of 8.3% during the forecast period.
Published: 2025-03-10
Pages: 82
USD 2900.00 (Single User License)Global and United States KRAS Inhibitor Market Report & Forecast 2024-2030
KRAS inhibitors are a class of targeted cancer therapies designed to block the activity of the KRAS protein, a common driver of cancer, particularly in pancreatic, colorectal, and lung cancers. KRAS mutations are notoriously difficult to target because the protein has a smooth surface with few pockets for drug binding. However, recent advances have led to the development of specific inhibitors, such as sotorasib and adagrasib, which target the G12C mutation in KRAS, a mutation present in a subset of cancers. These inhibitors work by irreversibly binding to the mutant KRAS protein, preventing it from signaling the uncontrolled cell growth that leads to cancer. While these drugs have shown promise, they are not universally effective, and resistance often develops, leading to ongoing research to improve their efficacy and expand their use to other KRAS mutations.
Published: 2024-09-11
Pages: 120
USD 4350.00 (Single User License)Global KRAS Inhibitor Market Research Report 2024
KRAS inhibitors are a class of targeted cancer therapies designed to block the activity of the KRAS protein, a common driver of cancer, particularly in pancreatic, colorectal, and lung cancers. KRAS mutations are notoriously difficult to target because the protein has a smooth surface with few pockets for drug binding. However, recent advances have led to the development of specific inhibitors, such as sotorasib and adagrasib, which target the G12C mutation in KRAS, a mutation present in a subset of cancers. These inhibitors work by irreversibly binding to the mutant KRAS protein, preventing it from signaling the uncontrolled cell growth that leads to cancer. While these drugs have shown promise, they are not universally effective, and resistance often develops, leading to ongoing research to improve their efficacy and expand their use to other KRAS mutations.
Published: 2024-09-11
Pages: 78
USD 2900.00 (Single User License)Global KRAS Inhibitor Market Insights, Forecast to 2030
KRAS inhibitors are a class of targeted cancer therapies designed to block the activity of the KRAS protein, a common driver of cancer, particularly in pancreatic, colorectal, and lung cancers. KRAS mutations are notoriously difficult to target because the protein has a smooth surface with few pockets for drug binding. However, recent advances have led to the development of specific inhibitors, such as sotorasib and adagrasib, which target the G12C mutation in KRAS, a mutation present in a subset of cancers. These inhibitors work by irreversibly binding to the mutant KRAS protein, preventing it from signaling the uncontrolled cell growth that leads to cancer. While these drugs have shown promise, they are not universally effective, and resistance often develops, leading to ongoing research to improve their efficacy and expand their use to other KRAS mutations.
Published: 2024-09-11
Pages: 139
USD 4900.00 (Single User License)
CHOOSE LICENSE TYPE
USD 3950.00
USD 5925.00
USD 7900.00
Add to Cart
Buy Now
HAVE A QUESTION?
General Email:
REPORT COVERAGE
DESCRIPTION
OVERVIEW
MARKET SEGMENTATION
CHAPTER OUTLINE
QYRESEARCH'S STRENGTHS
TABLE OF CONTENTS
TABLE OF FIGURES
RLEATED REPORTS
INTEREST IN THIS REPORT?
Get A Free Sample
Request For Quotation
OR
NEED A CUSTOMIZED REPORT?
Customized Report
Request Sample
Pre-Order Enquiry
Add to Cart
Buy Now